FrancophonIA/ELRC3.0 huggingface dataset:
English: Gastrointestinal haemorrhage Pancreatitis Anorexia Dyspepsia Constipation Gastrointestinal disorder
Maltese: Emorraġija gastrointestinali Pankreatite Anoreksja Dispepsja Stitikezza Disturb gastrointestinali
English: The mean recovery of 2-amino-5, 6-dichloro-3, 4-dihydroquinazoline in urine is approximately 18-35% of the administered dose.
Maltese: L-irkupru medju ta' 2-amino-5, 6-dichloro-3, 4-dihydroquinazoline fl-awrina huwa ta' bejn wieħed u ieħor 18-35% tad-doża mogħtija.
English: Anagrelide is primarily metabolised by CYP1A2 to form, 3-hydroxy anagrelide, which is further metabolised via CYP1A2 to the inactive metabolite, 2-amino-5, 6-dichloro-3, 4-dihydroquinazoline.
Maltese: Anagrelide huwa primarjament metabolizzat minn CYP1A2 biex jifforma 3-hydroxy-anagrelide, li jiġi metabolizzat b'mod ulterjuri permezz ta' CYP1A2 għall-metabolit inattiv 2-amino-5, 6-dichloro-3, 4-dihydroquinazoline.
English: Reproductive toxicology
Maltese: Tossiċità fis-sistema riproduttiva
English: Currently available data are described in sections 4.4, 4.8, 5.1 and 5.2, but no recommendation on a posology can be made.
Maltese: Id-data disponibbli attwalment hija deskritta fis-sezzjonijiet 4.4, 4.8, 5.1 u 5.2, iżda ma tista' ssir l-ebda rakkomandazzjoni dwar il-pożoloġija.
English: Pack size: 100 hard capsules.
Maltese: Daqs tal-pakkett: 100 kapsula iebsa.
English: • Potentially life-threatening, irregular heart beat (torsade de pointes);
Maltese: • Taħbit irregolari tal-qalb potenzjalment fatali (torsade de pointes);
English: • Anagrelide is primarily metabolised by CYP1A2.
Maltese: • Anagrelide huwa metabolizzat primarjament minn CYP1A2.
English: Lactose monohydrate Croscarmellose sodium
Maltese: Croscarmellose sodium
English: 117 Allée des Parcs, Saint-Priest,
Maltese: 117 Allée des Parcs,
English: INFORMATION IN BRAILLE Carton only: anagrelide mylan 0.5 mg
Maltese: INFORMAZZJONI BIL-BRAILLE Kartuna biss: anagrelide mylan 0.5 mg
English: • Anagrelide may cause intestinal disturbance in some patients and compromise the absorption of hormonal oral contraceptives.
Maltese: • Anagrelide jista' jikkaġuna disturbi intestinali f'xi pazjenti u jikkomprometti l-assorbiment ta' kontraċettivi ormonali orali.
English: It is not recommended in patients with elevated transaminases (> 5 times the upper limit of normal) (see sections 4.2 and 4.3).
Maltese: Mhux rrakkomandat f'pazjenti bi transaminases għoljin (> 5 darbiet il-limitu ta' fuq tan-normal) (ara sezzjonijiet 4.2 u 4.3).
English: Pharmacokinetic data from fasting elderly patients with ET (age range 65 - 75 years) compared to fasting adult patients (age range 22 - 50 years) indicate that the Cmax and AUC of anagrelide were 36% and 61% higher respectively in elderly patients, but that the Cmax and AUC of the active metabolite, 3hydroxy anagrelide, were 42% and 37% lower respectively in the elderly patients.
Maltese: Dejta farmakokinetika minn pazjenti anzjani fl-istat sajjem b'ET (età ta' bejn il-65 u l-75 sena) meta mqabbla ma' pazjenti adulti fl-istat sajjem (età ta' bejn it-22 u l-50 sena) tindika li s-Cmax u l-AUC ta' anagrelide kienu 36% u 61% ogħla rispettivament f'pazjenti anzjani, iżda li s-Cmax u l-AUC talmetabolit attiv, 3-hydroxy anagrelide, kienu 42% u 37% iktar baxxi fil-pazjenti anjani.
English: Microcrystalline cellulose
Maltese: Povidone (K29/32)Microcrystalline cellulose
English: During clinical development doses of 10 mg/day have been used.
Maltese: Waqt żvilupp kliniku ntużaw dożi ta' 10 mg/jum.
English: 100 hard capsules
Maltese: 100 kapsula iebsa.
English: INFORMATION IN BRAILLE Carton only: anagrelide mylan 1 mg
Maltese: INFORMAZZJONI BIL-BRAILLE Kartuna biss: anagrelide mylan 1 mg
English: Anagrelide Mylan contains the active substance, anagrelide.
Maltese: Anagrelide Mylan fih is-sustanza attiva anagrelide.
English: Patients with moderate or severe renal impairment (creatinine clearance < 50 ml/min).
Maltese: Pazjenti b'indeboliment renali moderat jew serju (rata ta' eliminazzjoni tal-kreatinina < 50 ml/min). 4.4
English: Name and address of the manufacturers responsible for batch release SYNTHON HISPANIA, S.L.
Maltese: Isem u indirizz tal-manifatturi responsabbli għall-ħruġ tal-lott SYNTHON HISPANIA, S.L.
English: The other ingredients are lactose (see section 2 ‘Anagrelide Mylan contains lactose'), croscarmellose sodium, povidone, microcrystalline cellulose, magnesium stearate, gelatin, titanium dioxide (E171) and iron oxide black (E172).
Maltese: Is-sustanzi mhux attivi l-oħra huma lactose (ara sezzjoni 2, ‘Atazanavir Mylan fih il-lactose'), croscarmellose sodium, povidone, microcrystalline cellulose, magnesium stearate, gelatin, titanium dioxide (E171) u iron oxide black (E172).
English: UNIQUE IDENTIFIER - 2D BARCODE Carton only:
Maltese: IDENTIFIKATUR UNIKU - BARCODE 2D Kartuna biss: barcode 2D li jkollu l-identifikatur uniku inkluż.
English: Mutagenic and carcinogenic potential
Maltese: Potenzjal mutaġeniku u karċinoġeniku
English: • Anagrelide is an inhibitor of PDE III.
Maltese: • Anagrelide huwa impeditur ta' PDE III..
English: Dose proportionality has been found in the dose range 0.5 mg to 2 mg.
Maltese: Il-proporzjonalità fid-doża nstabet f'medda ta' doża li tvarja minn 0.5 mg sa 2 mg.
English: The capsule size is approximately 14.3 x 5.3 mm.
Maltese: Id-daqs tal-kapsula hu ta' madwar 14.3 x 5.3 mm.
English: CYP1A2 inhibitors
Maltese: Inibituri ta' CYP1A2
English: There was also a trend to higher dose-normalised exposure to the active metabolite.
Maltese: Kien hemm ukoll tendenza għal esponiment ogħla normalizzat skont id-doża għal metabolit attiv.
English: Gastrointestina l disorders
Maltese: Distubi gastrointestinali
English: The other ingredients are lactose (see section 2 ‘Anagrelide Mylan contains lactose'), croscarmellose sodium, povidone, microcrystalline cellulose, magnesium stearate, gelatin and titanium dioxide(E171).
Maltese: Is-sustanzi mhux attivi l-oħra huma lactose (ara sezzjoni 2, ‘Atazanavir Mylan fih il-lactose'), croscarmellose sodium, povidone, microcrystalline cellulose, magnesium stearate, gelatin u titanium dioxide (E171).
English: • A clinical interaction study performed in healthy subjects showed that co-administration of repeat-dose anagrelide 1 mg once daily and acetylsalicylic acid 75 mg once daily may enhance the anti-platelet aggregation effects of each active substance compared with administration of acetylsalicylic acid alone.
Maltese: • Studju dwar interazzjoni klinika li sar fuq persuni b'saħħithom wera li l-għoti flimkien ta' doża ripetuta ta' anagrelide 1 mg darba kuljum u acetylsalicylic acid 75 mg darba kuljum jista' jtejjeb l-effetti tal-aggregazzjoni tal-anti-plejtlits ta' kull sustanza attiva meta mqabbel mal-għoti ta' acetylsalicylic acid waħdu.
English: The safety and efficacy of anagrelide as a platelet lowering agent have been evaluated in four openlabel, non-controlled clinical trials (study numbers 700-012, 700-014, 700-999 and 13970-301) including more than 4,000 patients with myeloproliferative neoplasms (MPNs).
Maltese: Is-sigurtà u l-effikaċja ta' anagrelide bħala mediċina li tbaxxi l-għadd tal-plejtlets kienu evalwati f'erba' provi kliniċi open-label u mhux ikkontrollati (in-numri tal-istudji 700-012, 700-014, 700-999 u 13970-301) li inkludew aktar minn 4,000 pazjent b'neoplażmi majeloproliferattivi (MPNs).
English: Each capsule contains approximately 119 mg lactose.
Maltese: Kull kapsula fiha madwar 119 mg ta' lactose.
English: There are limited pharmacokinetic data for this patient population.
Maltese: Hemm dejta farmakokinetika limitata għal din il-popolazzjoni ta' pazjenti.
English: Each capsule contains approximately 59.5 mg lactose.
Maltese: Kull kapsula fiha madwar 59.5 mg ta' lactose.
English: The most commonly reported adverse reactions associated with anagrelide were headache occurring at approximately 14%, palpitations occurring at approximately 9%, fluid retention and nausea both occurring at approximately 6% and diarrhoea occurring at 5%.
Maltese: L-aktar reazzjoni avversa komuni rrapportata assoċjata ma' anagrelide kienet l-uġigħ ta' ras li seħħ f'madwar 14%, palpitazzjonijiet li seħħew, f'madwar 9%, akkumulazzjoni ta' fluwidu u nawsja li t-tnejn seħħew f'madwar 6%, u dijarea li seħħet f'5%.
English: Pharmacokinetic data from exposed fasting children and adolescents (age range 7 - 16 years) with essential thrombocythaemia indicate that dose normalised exposure, Cmax and AUC, of anagrelide tended to be higher in children/adolescents compared with adults.
Maltese: Dejta farmakokinetika minn tfal u adolexxenti sajmin esposti (età ta' bejn 7 u 16-il sena) bi tromboċitemja essenzjali indikat li esponimenti nnormalizzati tad-doża, is-Cmax u l-AUC ta' anagrelide kellhom tendenza li jkunu ogħla fit-tfal/adolexxenti meta mqabbla ma' tal-adulti.
English: 6545 CM Nijmegen NETHERLANDS
Maltese: Nijmegen In-Netherlands
English: Anagrelide Mylan contains less than 1 mmol sodium (23 mg) per capsule, that is to say essentially ‘sodium-free'.
Maltese: Anagrelide Mylan fih anqas minn 1 mmol sodium (23 mg) f'kull kapsula, jiġifieri essenzjalment ‘ħieles mis-sodium'.
English: The effects of medicinal products with similar properties such as the inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.
Maltese: L-effetti ta' prodotti mediċinali bi kwalitajiet simili bħall-inotropi milrinone, enoximone, amrinone, olprinone u cilostazol jistgħu jiħraxu permezz ta' anagrelide.
English: A capsule size 4 (approximately 14.3 x 5.3 mm) with a grey body and cap.
Maltese: Kapsula ta' daqs 4 (madwar 14.3 x 5.3 mm) b'korp u għatu griżi.
English: Following oral administration of anagrelide in man, at least 70% is absorbed from the gastrointestinal tract.
Maltese: Wara l-għoti orali ta' anagrelide fil-bniedem, tal-anqas 70% jiġi assorbit mill-passaġġ gastrointestinali.
English: Less than 1% is recovered in the urine as anagrelide.
Maltese: Anqas minn 1% huwa rkuprat fl-awrina bħala anagrelide.
English: • Anagrelide demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other co-administered medicinal products sharing that clearance mechanism e.g. theophylline.
Maltese: • Anagrelide juri xi attività inibitorja limitata lejn CYP1A2 li tista' tippreżenta potenzjal teoretiku għal interazzjoni ma' prodotti mediċinali oħrajn mogħtija flimkien li għandhom l-istess mekkaniżmu ta' eliminazzjoni eż. theophylline.
English: How to store Anagrelide Mylan
Maltese: Tiħux Anagrelide Mylan
English: It is known that CYP1A2 is inhibited by several medicinal products, including fluvoxamine and enoxacin, and such medicinal products could theoretically adversely influence the clearance of anagrelide.
Maltese: Huwa magħruf li CYP1A2 huwa impedut minn diversi prodotti mediċinali, li jinkludu fluvoxamine u enoxacin, u prodotti mediċinali bħal dawn jistgħu teoritikament jinfluwenzaw b'mod ħażin ir-rata ta' l-eliminazzjoni ta' anagrelide.
English: Anagrelide Mylan contains sodium
Maltese: Anagrelide Mylan fih is-sodium
English: Tinnitus
Maltese: Tinfaraġ
English: These differences were likely to be caused by lower presystemic metabolism of anagrelide to 3-hydroxy anagrelide in the elderly patients.
Maltese: Dawn iddifferenzi kienu x'aktarx ikkawżati minn metaboliżmu presistemiku iktar baxx ta' anagrelide għal 3-hydroxy anagrelide fil-pazjenti anzjani.
English: • Fluvoxamine, used to treat depression;
Maltese: • Fluvoxamine, li jintuża biex jittratta d-dipressjoni;
English: In studies 700-012, 700-014, 700-999 and study 13970-301 the time to complete response ranged from 4 to 12 weeks.
Maltese: Il-ħin biex jintlaħaq rispons komplut fl-istudji 700-012, 700-014, 700-999 u l-istudju 13970-301 varja minn 4 sa 12-il ġimgħa.
English: High-density polyethylene (HDPE) bottle of 30 ml or 75 ml with a tamper evident, child-resistant polypropylene (PP) closure with a desiccant.
Maltese: In-natura tal-kontenitur u ta' dak li hemm ġo fih Flixkun ta' high-density polyethylene (HDPE) ta' 30 mL jew 75 mL b'għatu tal-polypropylene (PP) li ma jinfetaħx mit-tfal u kontra t-tbagħbis, b'dessikant.
English: Tubulointerstitial nephritis
Maltese: Nefrite tubulointerstizj ali
English: 48 patients aged 6-17 years (19 children and 29 adolescents) have received anagrelide for up to 6.5 years either in clinical studies or as part of a disease registry (see section 5.1).
Maltese: 48 pazjent li kellhom 6--17-il sena (19 tfal u 29 adolexxent) irċivew anagrelide għal sa 6.5 snin jew fi studji kliniċi jew bħala parti minn reġistru ta' mard (ara sezzjoni 5.1).
English: Anagrelide 0.5 mg hard capsules
Maltese: Anagrelide 0.5 mg kapsuli ibsin
English: Myocardial infarction Cardiomyopathy Cardiomegaly Pericardial effusion
Maltese: Infart mijokardijali Kardjomijopatij a
English: Very limited data are available on the use of anagrelide in the paediatric population and anagrelide should be used in this patient group with caution (see sections 4.2, 4.8, 5.1 and 5.2).
Maltese: Hemm data limitata ħafna dwar l-użu ta' anagrelide fil-popolazzjoni pedjatrika u anagrelide għandu jintuża b'kawtela f'dan il-grupp ta' pazjenti (ara sezzjonijiet 4.2, 4.8, 5.1 u 5.2).
English: In earlier, open-label studies, median platelet count reductions were observed in 7 children and 9 adolescents treated for between 3 months and 6.5 years.
Maltese: Fi studji open-label iktar bikrin, tnaqqis fil-medjan tal-għadd tal-plejtlits ġie osservat f'7 itfal u 9 adolexxenti ttrattati għal bejn 3 xhur u 6.5 snin.
English: Typically, a fall in the platelet count will be observed within 14 to 21 days of starting treatment and in most patients an adequate therapeutic response will be observed and maintained at a dose of 1 to 3 mg/day (for further information on the clinical effects refer to section 5.1).
Maltese: Tipikament, tnaqqis fl-għadd tal-plejtlets għandu jiġi osservat fi żmien 14 sa 21 ġurnata minn mindu jinbeda t-trattament u fil-parti l-kbira tal-pazjenti reazzjoni terapewtika adegwata tiġi osservata u miżmuma f'doża ta' 1 sa 3 mg/jum (għal aktar informazzjoni fuq l-effetti kliniċi ara sezzjoni 5.1).
English: Anagrelide at ≥ 60 mg/kg increased parturition time and mortality in the dam and foetus respectively.
Maltese: Anagrelide f'doża ta' ≥60 mg/kg żied it-tul tal-ħin tal-ħlas u l-mortalità fl-ommijiet firien u l-feti rispettivament.
English: LIST OF EXCIPIENTS Contains lactose and sodium.
Maltese: TA' EĊĊIPJENTI Fih lactose u sodium.
English: Pharmacokinetic data from healthy subjects established that food decreases the Cmax of anagrelide by 14%, but increases the AUC by 20%.
Maltese: Dejta farmakokinetika minn individwi f'saħħithom stabbilixxiet li l-ikel inaqqas is-Cmax ta' anagrelide b'14% imma jżid l-AUC b'20%.
English: Serious cardiovascular adverse reactions including cases of torsade de pointes, ventricular tachycardia, cardiomyopathy, cardiomegaly and congestive heart failure have been reported (see section 4.8).
Maltese: Reazzjonijiet avversi kardjovaskulari serji li jinkludu każijiet ta' torsade de pointes, takikardija ventrikulari, kardjomijopatija, kardjomegalija u insuffiċjenza konġestiva tal-qalb ġew irrappurtati (ara sezzjoni 4.8).
English: • Lung inflammation (signs include fever, coughing, difficulty breathing, wheezing; which causes scaring of the lungs) (allergic alveolitis, including interstitial lung disease, pneumonitis);
Maltese: • Infjammazzjoni tal-pulmun (sinjali jinkludu deni, sogħla, diffikultà biex tieħu n-nifs, tħarħir; li tikkawża ċikatriċi tal-pulmun) (alveolite allerġika, li tinkludi mard interstizjali tal-pulmun,
English: Depression Amnesia Confusion Insomnia Paraesthesia Hypoaesthesia Nervousness Dry mouth
Maltese: Dipressjoni Amnesija Konfużjoni Nuqqas ta' rqad Parestesija Ipoestesija Nervożità Ħalq niexef
English: • At the doses recommended for use in the treatment of essential thrombocythaemia, anagrelide may potentiate the effects of other medicinal products that inhibit or modify platelet function e.g. acetylsalicylic acid.
Maltese: • Fid-dożi rakkomandati għal użu fit-trattament ta' tromboċitemja essenzjali, anagrelide jista' jqawwi l-effetti ta' prodotti mediċinali oħra li jimpedixxu jew jimmodifikaw il-funzjoni talplejtlets eż.acetylsalicylic acid.
English: Anagrelide 1 mg hard capsules
Maltese: Anagrelide 1 mg kapsuli ibsin
English: At the NOEL dose (30 mg/kg/day), the AUCs for anagrelide and the metabolites BCH24426 and RL603 were 425-, 31- and 13-fold higher than the AUC in humans administered an oral dose of anagrelide 2 mg/day, respectively.
Maltese: Fid-doża NOEL (30 mg/kg/jum), l-AUCs għal anagrelide u l-metaboliti BCH24426 u RL603 kienu 425, 31 u 13-il darba ogħla mill-AUC fi bnedmin li ngħataw doża orali ta' anagrelide ta' 2 mg/jum, rispettivament.
English: Evidence of similar in vivo actions was observed in bone marrow biopsy samples from treated patients.
Maltese: Evidenza ta' azzjonijiet simili in vivo kienet osservata f'kampjuni tal-bijopsiji mill-mudullun ta' pazjenti trattati.
English: • Certain types of antibiotic, such as enoxacin, used to treat infections;
Maltese: • Ċertu tip ta' antibijotiċi, bħal enoxacin, li jintuża biex jittratta infezzjonijiet;
English: • In vivo interaction studies in humans have demonstrated that digoxin and warfarin do not affect the pharmacokinetic properties of anagrelide.
Maltese: • Studji in vivo dwar l-interazzjonijiet fil-bnedmin urew li digoxin u warfarin ma jaffettwawx ilpropjetajiet farmakokinetici ta' anagrelide.
English: The majority of adverse events observed were among those listed in the SmPC.
Maltese: Il-maġġoranza tal-avvenimenti avversi osservati kienu fost dawk elenkati fl-SmPC.
English: Use of concomitant anagrelide and acetylsalicylic acid has been associated with major haemorrhagic events (see section 4.5).
Maltese: L-użu ta' anagrelide u acetylsalicylic acid fl-istess ħin ġie assoċjat ma' avvenimenti maġġuri ta' emorragija (ara sezzjoni 4.5).
English: Anagrelide Mylan 1 mg hard capsules
Maltese: Anagrelide Mylan 1 mg kapsuli ibsin
English: Anagrelide Mylan 1 mg hard capsules anagrelide
Maltese: Anagrelide Mylan 1 mg kapsuli ibsin anagrelide
English: A capsule size 4 (approximately 14.3 x 5.3 mm) with an opaque white body and cap.
Maltese: Kapsula ta' daqs 4 (madwar 14.3 x 5.3 mm) b'korp u għatu bojod u opaki.
English: Interstitial lung disease including pneumonitis and allergic alveolitis
Maltese: Mard interstizjali talpulmun li jinkludi pnewmonite u alveolite allerġika
English: Anagrelide Mylan 0.5 mg hard capsules anagrelide
Maltese: Anagrelide Mylan 0.5 mg kapsuli ibsin anagrelide
English: A specific antidote for anagrelide has not been identified.
Maltese: Ma ġie identifikat l-ebda antidot għal anagrelide.
English: Children should be monitored regularly for disease progression according to standard clinical practices, such as physical examination, assessment of relevant disease markers and bone marrow biopsy.
Maltese: It-tfal għandhom jiġu mmonitorjati regolarment għal progressjoni tal-marda skont il-prattiċi kliniċi standard, bħal eżami fiżiku, evalwazzjoni ta' markaturi ta' mard rilevanti, u bijopsija tal-mudullun.
English: Among them, the incidence of adrenal phaeochromocytomas was increased relative to control in males at all dose levels (≥ 3 mg/kg/day) and in females receiving 10 mg/kg/day and above.
Maltese: Fosthom, l-inċidenza ta' phaeochromocytomas adrenali żdiedet meta mqabbla mal-kontroll fil-firien maskili fil-livelli kollha tad-doża (≥ 3 mg/kg/kuljum) u fil-firien femminili li kienu qed jirċievu 10 mg/kg/kuljum u aktar.
English: • Theophylline, used to treat severe asthma and breathing problems;
Maltese: • Theophylline, li jintuża biex jittratta problemi severi tal-ażżma u tan-nifs;
English: Therapy requires close clinical supervision of the patient which will include a full blood count (haemoglobin and white blood cell and platelet counts), assessment of liver function (ALT and AST), renal function (serum creatinine and urea) and electrolytes (potassium, magnesium and calcium).
Maltese: It-terapija teħtieġ sorveljanza klinika mill-qrib tal-pazjent li għandha tinkludi l-għadd tad-demm komplut (emohlobina u l-għadd ta' ċelluli bojod tad-demm u tal-plejtlets), stima tal-funzjoni tal-fwied (ALT u AST), tal-funzjoni renali (kreatinina fis-serum u urea) u elettroliti (potassium, magnesium u calcium).
English: This medicine contains less than 1 mmol sodium (23 mg) per capsule, that is to say essentially ‘sodium-free'.
Maltese: Din il-mediċina fiha anqas minn 1 mmol sodium (23 mg) f'kull kapsula, jiġifieri essenzjalment ‘ħieles mis-sodium'.
English: Rare side effects: may affect up to 1 in 1,000 people Bleeding gums, weight gain, severe chest pain (angina pectoris), heart muscle disease, (signs include fatigue, chest pain and palpitations), enlarged heart, accumulation of fluid around the heart, loss of coordination, difficulty in speaking, dry skin, migraine, visual disturbances or double vision, ringing in the ears, dizziness on standing up (especially when getting up from a sitting or lying position), increased need to pass water at night, pain, ‘flu-like' symptoms, sleepiness, widening of blood vessels, inflammation of the large bowel (signs include: diarrhoea, usually with blood and mucus, stomach pain, fever), inflammation of the stomach (signs include: pain, nausea, vomiting), area of abnormal density in the lung, increased creatinine level in blood tests, which may be a sign of kidney problems.
Maltese: Effetti sekondarji rari: jistgħu jaffettwaw sa 1 minn kull 1,000 persuna Fsada fil-ħanek, żieda fil-piż, uġigħ sever fis-sider (anġina pectoris), mard fil-muskolu tal-qalb (sinjali jinkludu għeja, uġigħ fis-sider u palpitazzjonijiet), qalb imkabbra, akkumulazzjoni ta' fluwidu madwar il-qalb, telf fil-koordinazzjoni, diffikultà meta wieħed jitkellem, ġilda xotta, emigranja, disturbi filvista jew vista doppja, żanżin fil-widnejn, sturdament meta tqum bilwieqfa (speċjalment meta tqum minn pożizzjoni bilqiegħda jew mimduda), bżonn aktar ta' spiss biex tagħmel l-awrina bil-lejl, uġigħ, sintomi jixbħu l-influwenza, ngħas, twessigħ tal-vini/arterji tad-demm, infjammazzjoni tal-musrana l-kbira (sinjali jinkludu: dijarea, normalment bid-demm u mukus, uġigħ fl-istonku, deni), infjammazzjoni tal-istonku (sinjali jinkludu: uġigħ, dardir, rimettar), żona ta' densità mhux normali filpulmun, żieda fil-livell tal-kreatinina fit-testijiet tad-demm, li tista' tkun sinjal ta' problemi fil-kliewi.
English: In this study 34 patients received anagrelide for up to 5 years.
Maltese: F'dan l-istudju 34 pazjent irċevew anagrelide sa 5 snin.
English: Anagrelide Mylan 0.5 mg hard capsules
Maltese: Anagrelide Mylan 0.5 mg kapsuli ibsin
English: • Medicines that can alter your heart rhythm e.g. sotalol, amiodarone;
Maltese: • Mediċini li jistgħu jibdlu r-ritmu tat-taħbit tal-qalb tiegħek eż. sotalol, amiodarone;
English: Arthralgia Myalgia Back pain
Maltese: Artralġja Mijalġja Uġigħ fid-dahar
English: The NOEL (10 mg/kg/day) to this effect was 143, 12 and 11-fold higher than the AUC in humans administered a dose of anagrelide 2 mg/day, and the metabolites BCH24426 and RL603, respectively.
Maltese: L-NOEL (10 mg/kg/jum) għal dan l-effett kien ta' 143, 12 u 11-il darba ogħla mill-AUC fil-bnedmin li ngħataw doża ta' anagrelide ta' 2 mg/jum, u l-metaboliti BCH24426 u RL603, rispettivament.
English: Reported symptoms include sinus tachycardia and vomiting.
Maltese: Sintomi rrapportati jinkludu takikardja tas-sinus u rimettar.
English: • In vivo interaction studies in humans have demonstrated that anagrelide does not affect the pharmacokinetic properties of digoxin or warfarin.
Maltese: • Studji ta' interazzjonijiet in vivo fil-bnedmin urew li anagrelide ma jaffettwax il-kwalitajiet farmakokinetiċi ta' digoxin jew warfarin.
English: Concomitant use of anagrelide with other PDE III inhibitors such as milrinone, amrinone, enoximone, olprinone and cilostazol is not recommended.
Maltese: L-użu ta' anagrelide flimkien ma' impedituri oħrajn ta' PDE III bħal ma huma milrinone, amrinone, enoximone, olprinone u cilostazol mhux rakkomandat.